Obstructive Sleep Apnea (OSA) is an independent risk factor for hypertension (HTN) and the most common cause of resistant HTN. The mechanisms underlying OSA-associated HTN are not completely understood. This is crucial to find novel therapeutic targets of OSA-associated HTN. The Aryl Hydrocarbon Receptor (AHR) is a cytosolic transcription factor that has been linked with the pathogenesis of HTN. This study aims to evaluate the role of endogenous ligands of AHR such as kynurenine in discriminating patients with OSA-associated HTN. For that aim, a case-control study will be performed in patients with and without hypertension exposed and not exposed to OSA. Kynurenine and other metabolites will be quantified in urine and serum samples.
Study Type
OBSERVATIONAL
Enrollment
203
Centro Hospitalar de Lisboa Central
Lisbon, Portugal
Centro Hospitalar Lisboa Ocidental
Lisbon, Portugal
Hospital Beatriz Ângelo
Lisbon, Portugal
Hospital da Luz
Lisbon, Portugal
Hospital Fernando Fonseca
Lisbon, Portugal
Kynurenine / Tryptophan ratio
Ratio between kynurenine and tryptophan concentrations
Time frame: Day 1 (visit 1)
Concentrations of metabolites
The relevant metabolites and their concentration will be identified by Partial Least Square Discriminant Analysis (PLS-DA) applied to non-targeted metabolomics.
Time frame: Day 1 (visit 1)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.